Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy

References

• Precision Medicine Initiative (PMI) Working Group. The precision medicine initiative cohort program – building a research foundation for 21st century medicine. Precis. Med. Initiat. Work. Gr. Rep. to Advis. Comm. to Dir. NIH. 2015.
   Google Scholar
• Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2003;57(1):6–14.
   Web of Science ®Google Scholar
• Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol. 2009;76(2):215–228.
   PubMed Web of Science ®Google Scholar
• Farkouh A, Riedl T, Gottardi R, et al. Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: a review of the literature. Adv Ther. 2020;37(2):644–655.
   PubMed Web of Science ®Google Scholar
• Bartelink IH, Rademaker CMA, Schobben AFAM, et al. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet. 2006;45(11):1077–1097.
   PubMed Web of Science ®Google Scholar
• Hu M, Mak VWL, Yin OQP, et al. Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin. Drug Metab Pharmacokinet. 2013;28(2):104–108.
   PubMed Web of Science ®Google Scholar
• Caesar LK, Cech NB. Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2. Nat Prod Rep. 2019;36(6):869–888.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci. 2006;27(5):425–446.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol. 2008;21(1):70–83.
   PubMed Web of Science ®Google Scholar
• Williams JA, Hyland R, Jones BC, et al. Drug-drug interactions for udp-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCI/AUC) ratios. Drug Metab Dispos. 2004;32(11):1201–1208.
   PubMed Web of Science ®Google Scholar
• Clarke JD, Novak P, Lake AD, et al. Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease. Liver Int. 2017;37(7):1074–1081.
   PubMed Web of Science ®Google Scholar
• Montonye ML, Tian DD, Arman T, et al. A pharmacokinetic natural product-disease-drug interaction: A double hit of silymarin and nonalcoholic steatohepatitis on hepatic transporters in a rat model. J Pharmacol Exp Ther. 2019;371(2):385–393.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Fredrikson H, Neuvonen PJ, et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007;82(6):726–733.
   PubMed Web of Science ®Google Scholar
• Badri P, Dutta S, Coakley E, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant. 2015;15(5):1313–1322.
   PubMed Web of Science ®Google Scholar
• Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63(1):20–29.
   PubMed Web of Science ®Google Scholar
• Azuma J, Hasunuma T, Kubo M, et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol. 2012;68(1):29–37.
   PubMed Web of Science ®Google Scholar
• Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE. Drug Metab Pharmacokinet. 2005;20(1):55–64.
   PubMedGoogle Scholar
• Harvey V, Slevin M, Dilloway M, et al. The influence of cimetidine on the pharmacokinetics of 5‐fluorouracil. Br J Clin Pharmacol. 1984;18(3):421–430.
   PubMed Web of Science ®Google Scholar
• Iyer SV, Harpaz R, LePendu P, et al. Mining clinical text for signals of adverse drug-drug interactions. J Am Med Informatics Assoc. 2014;21(2):353–362.
   PubMed Web of Science ®Google Scholar
• Yu J, Zhou Z, Tay-Sontheimer J, et al. Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. food and drug administration between 2013 and 2016. Drug Metab Dispos. 2018;46(6):835–845. .
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999;39(1):1–17.
   PubMed Web of Science ®Google Scholar
• Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38(1):41–57.
   PubMed Web of Science ®Google Scholar
• Cicali EJ, Smith DM, Duong BQ, et al. A scoping review of the evidence behind cytochrome P450 2D6 isoenzyme inhibitor classifications. Clin Pharmacol Ther. 2020;108(1):116–125.
   PubMed Web of Science ®Google Scholar
• Hollenberg PF. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab Rev. 2002;34(1–2):17–35.
   PubMed Web of Science ®Google Scholar
• Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 1998;38(1):389–430.
   PubMedGoogle Scholar
• Ahonen J, Olkkola KT, Neuvonen PJ. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol. 1997;51(5):415–419.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Zhao P, Zhang L, et al. In vitro–in vivo extrapolation of metabolism- and transporter-mediated drug–drug interactions—overview of basic prediction methods. J Pharm Sci. 2017;106(9):2209–2213.
   PubMed Web of Science ®Google Scholar
• Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers | FDA [Internet]. 2020 [cited 2020 Aug 20]. Available from: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers.
   Google Scholar
• Hillgren KM, Keppler D, Zur AA, et al. Emerging transporters of clinical importance: an update from the international transporter consortium. Clin Pharmacol Ther. 2013;94(1):52–63.
   PubMed Web of Science ®Google Scholar
• Lau YY, Huang Y, Frassetto L, et al. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007;81(2):194–204.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112(1):71–105.
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693–705.
   PubMed Web of Science ®Google Scholar
• Keogh JP Membrane transporters in drug development [Internet]. 2012 [cited 2020 Sep 7]. p. 1–42. Available from: http://web.a.ebscohost.com/ehost/pdfviewer/pdfviewer?sid=7fe8b1bb-56a6-4c4f-b87d-02118619a084@sessionmgr4001&vid=2&hid=4114.
   Google Scholar
• Hézode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): A randomised, open-label trial. Lancet. 2015;385(9986):2502–2509.
   PubMed Web of Science ®Google Scholar
• Smith T, May G, Eckl V, et al. Market report. Off. Bot. Mark. Austin (TX); 2020.
   Google Scholar
• Geller AI, Shehab N, Weidle NJ, et al. Emergency department visits for adverse events related to dietary supplements. N Engl J Med. 2015;373(16):1531–1540.
   PubMed Web of Science ®Google Scholar
• Fenclova M, Novakova A, Viktorova J, et al. Poor chemical and microbiological quality of the commercial milk thistle-based dietary supplements may account for their reported unsatisfactory and non-reproducible clinical outcomes. Sci Rep. 2019;9(1):11118.
   PubMedGoogle Scholar
• Girennavar B, Poulose SM, Jayaprakasha GK, et al. Furocoumarins from grapefruit juice and their effect on human CYP 3A4 and CYP 1B1 isoenzymes. Bioorg Med Chem. 2006;14(8):2606–2612.
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Cancalon P, Widmer WW, et al. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol. 2011;7(3):267–286.
   PubMed Web of Science ®Google Scholar
• Lin HL, Kent UM, Hollenberg PF. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther. 2005;313(1):154–164.
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Kivistö K, Neuvonen P. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther. 1999;66(2):118–127.
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther. 1998;64(5):477–483.
   PubMed Web of Science ®Google Scholar
• Kantola T, Kivistö KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1998;63(4):397–402.
   PubMed Web of Science ®Google Scholar
• Glaeser H, Bailey DG, Dresser GK, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther. 2007;81(3):362–370.
   PubMed Web of Science ®Google Scholar
• Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs. 2004;4(5):281–297.
   PubMedGoogle Scholar
• Kirby BJ, Unadkat JD. Grapefruit juice, a glass full of drug interactions? Clin Pharmacol Ther. 2007;81(5):631–633.
   PubMed Web of Science ®Google Scholar
• Johnson EJ, González-Peréz V, Tian DD, et al. Selection of priority natural products for evaluation as potential precipitants of natural product-drug interactions: a NaPDI center recommended approach. Drug Metab Dispos. 2018;46(7):1046–1052.
   PubMed Web of Science ®Google Scholar
• Kellogg JJ, Paine MF, McCune JS, et al. Selection and characterization of botanical natural products for research studies: a NaPDI center recommended approach. Nat Prod Rep. 2019;36(8):1196–1221.
   PubMed Web of Science ®Google Scholar
• Paine MF, Shen DD, McCune JS. Recommended approaches for pharmacokinetic natural product-drug interaction research: a NaPDI center commentary. Drug Metab Dispos. 2018;46(7):1041–1045.
   PubMed Web of Science ®Google Scholar
• Elliott LS, Henderson JC, Neradilek MB, et al. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial. PLoS One. 2017;12(2):12.
   Web of Science ®Google Scholar
• PharmVar [Internet]. [cited 2020 Aug 24]. Available from: https://www.pharmvar.org/gene/CYP2D6.
   Google Scholar
• Medhasi S, Pasomsub E, Vanwong N, et al. Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in thai children and adolescents with autism spectrum disorder. Neuropsychiatr Dis Treat. 2016;12:843–851.
   PubMed Web of Science ®Google Scholar
• Belmonte C, Ochoa D, Román M, et al. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers. Basic Clin Pharmacol Toxicol. 2018;122(6):596–605.
   PubMed Web of Science ®Google Scholar
• Wang G, Lei H-P, Li Z, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol. 2009;65(3):281–285.
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–211.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet. 2001;40(8):587–603.
   PubMed Web of Science ®Google Scholar
• Aithal GP, Day CP, Kesteven PJL, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353(9154):717–719.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5(1):6–13.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006;25(11):1679–1691.
   PubMed Web of Science ®Google Scholar
• Aka I, Bernal CJ, Carroll R, et al. Clinical pharmacogenetics of cytochrome P450-associated drugs in children. J Pers Med. 2017;7(4):7.
   Web of Science ®Google Scholar
• Isvoran A, Louet M, Vladoiu DL, et al. Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. Drug Discov Today. 2017;22(2):366–376.
   PubMed Web of Science ®Google Scholar
• Saif MW, Lee AM, Offer SM, et al. A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. Mayo Clin Proc. 2014;89(1):131–136.
   PubMed Web of Science ®Google Scholar
• Lee AM, Shi Q, Pavey E, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014;106(12):106.
   Google Scholar
• Mattison LK, Fourie J, Desmond RA, et al. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res. 2006;12(18):5491–5495.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Gelderblom H, Marsh S, et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype*1. Clin Pharmacol Ther. 2004;76(1):38–44.
   PubMed Web of Science ®Google Scholar
• Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther. 2002;1(8):611–616.
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Ieiri I, Hirota T, et al. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos. 2005;33(1):94–101.
   PubMed Web of Science ®Google Scholar
• Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet. 1999;56(4):247–258.
   PubMed Web of Science ®Google Scholar
• Tamai I. Oral drug delivery utilizing intestinal OATP transporters. Adv Drug Deliv Rev. 2012;64(6):508–514.
   PubMed Web of Science ®Google Scholar
• Bluth M, Li J. Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy. Pharmgenomics Pers Med. 2011;4:11.
   PubMedGoogle Scholar
• Ahmed S, Zhou Z, Zhou J, et al. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genom Proteom Bioinform. 2016;14(5):298–313.
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for industry- pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing. Food Drug Adm. 2020.
   Google Scholar
• Renton KW, Mannering GJ. Depression of the hepatic cytochrome P 450 mono oxygenase system by administered tilorone (2,7 bis[2 (diethylamino)ethoxy]fluoren 9 one dihydrochloride). Drug Metab Dispos. 1976;4(3):223–231.
   PubMed Web of Science ®Google Scholar
• Haas CE, Kaufman DC, Jones CE, et al. Cytochrome P450 3A4 activity after surgical stress. Crit Care Med. 2003;31(5):1338–1346.
   PubMed Web of Science ®Google Scholar
• Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev. 1997;29(4):1129–1188.
   PubMed Web of Science ®Google Scholar
• Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer. 2002;87(3):277–280.
   PubMed Web of Science ®Google Scholar
• Fisher CD, Lickteig AJ, Augustine LM, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos. 2009;37(10):2087–2094.
   PubMed Web of Science ®Google Scholar
• Villeneuve J-P J-P, Pichette V. Cytochrome P450 and liver diseases. Curr Drug Metab. 2004;5(3):273–282.
   PubMed Web of Science ®Google Scholar
• Hardwick RN, Fisher CD, Canet MJ, et al. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2011;39(12):2395–2402.
   PubMed Web of Science ®Google Scholar
• Ali I, Slizgi JR, Kaullen JD, et al. Transporter-mediated alterations in patients with nash increase systemic and hepatic exposure to an OATP and MRP2 substrate. Clin Pharmacol Ther. 2018;104(4):749–756.
   Web of Science ®Google Scholar
• Ogasawara K, Terada T, Toshiya K, et al. Hepatitis c virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. Drug Metab Pharmacokinet. 2010;25(2):190–199.
   PubMed Web of Science ®Google Scholar
• Le Vee M, Lecureur V, Stieger B, et al. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos. 2009;37(3):685–693.
   PubMed Web of Science ®Google Scholar
• Maher JM, Dieter MZ, Aleksunes LM, et al. Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology. 2007;46(5):1597–1610.
   PubMed Web of Science ®Google Scholar
• Schrieber SJ, Wen Z, Vourvahis M, et al. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos. 2008;36(9):1909–1916.
   PubMed Web of Science ®Google Scholar
• Schrieber SJ, Hawke RL, Wen Z, et al. Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. Drug Metab Dispos. 2011;39(12):2182–2190.
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, et al. Rifampin decreases the plasma concentrations and effects of repaglinide. Clinical Pharmacology & Therapeutics. 2000;68:495–500 5 doi:10.1067/mcp.2000.111183
   PubMed Web of Science ®Google Scholar
• Thakkar N, Slizgi JR, Brouwer KLR. Effect of liver disease on hepatic transporter expression and function. J Pharm Sci. 2017;106(9):2282–2294.
   PubMed Web of Science ®Google Scholar
• Evers R, Piquette-Miller M, Polli JW, et al. Disease-associated changes in drug transporters may impact the pharmacokinetics and/or toxicity of drugs: a white paper from the international transporter consortium. Clin Pharmacol Ther. 2018;104(5):900–915. .
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Backman JT, Kurkinen KJ, et al., Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther. 84(4): 488–496. 2008.
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol. 2003;56(1):120–124.
   PubMed Web of Science ®Google Scholar
• Brunham LR, Lansberg PJ, Zhang L, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 2012;12(3):233–237. .
   PubMed Web of Science ®Google Scholar
• Jiang F, Choi J-Y, Lee J-H, et al. The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition. Pharmacogenomics. 2017;18(5):459–469.
   PubMed Web of Science ®Google Scholar
• World Health Organization. The top 10 causes of death [Internet]. 2014 [cited 2020 Sep 2]. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
   Google Scholar
• Pasanen MK, Neuvonen M, Neuvonen PJ, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006;16(12):873–879.
   PubMed Web of Science ®Google Scholar
• Meade T, Sleight P, Collins R, et al. SLCO1B1 variants and statin-induced myopathy - A genomewide study. N Engl J Med. 2008;359:789–799.
   PubMed Web of Science ®Google Scholar
• CDC FastStats - leading causes of death [Internet]. [cited 2020 Sep 2]. Available from: https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm.
   Google Scholar
• Xu J, Murphy SL, Kochanek KD, et al. Mortality in the United States, 2018 key findings data from the national vital statistics system. NCHS Data Brief. 2020;355:1–8.
   Google Scholar
• Yee SW, Giacomini MM, Hsueh C-H, et al., Metabolomic and genome-wide association studies reveal potential endogenous biomarkers for OATP1B1. Clin Pharmacol Ther. 100(5): 524–536. 2016.
   PubMed Web of Science ®Google Scholar
• Lai Y, Mandlekar S, Shen H, et al. Coproporphyrins in plasma and urine can be appropriate clinical biomarkers to recapitulate drug-drug interactions mediated by organic anion transporting polypeptide inhibition. J Pharmacol Exp Ther. 2016;358(3):397–404.
   PubMed Web of Science ®Google Scholar
• Yee SW, Giacomini MM, Shen H, et al. Organic anion transporter polypeptide 1b1 polymorphism modulates the extent of drug–drug interaction and associated biomarker levels in healthy volunteers. Clin Transl Sci. 2019;12(4):388–399.
   PubMed Web of Science ®Google Scholar
• Shen H, Chen W, Drexler DM, et al. Comparative evaluation of plasma bile acids, dehydroepiandrosterone sulfate, hexadecanedioate, and tetradecanedioate with coproporphyrins I and III as markers of OATP inhibition in healthy subjects. Drug Metab Dispos. 2017;45(8):908–919.
   PubMed Web of Science ®Google Scholar
• Poller B, Woessner R, Barve A, et al. Fevipiprant has a low risk of influencing co-medication pharmacokinetics: impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes. Pulm Pharmacol Ther. 2019;57:101809.
   PubMed Web of Science ®Google Scholar
• Duan P, Zhao P, Zhang L. Physiologically Based Pharmacokinetic (PBPK) modeling of pitavastatin and atorvastatin to predict Drug-Drug Interactions (DDIs). Eur J Drug Metab Pharmacokinet. 2017;42(4):689–705.
   PubMed Web of Science ®Google Scholar
• Varma MVS, Lai Y, Feng B, et al., Physiologically based modeling of pravastatin transporter- Mediated hepatobiliary disposition and Drug-Drug interactions. Pharm Res. 29(10): 2860–2873. 2012.
   PubMed Web of Science ®Google Scholar
• Jamei M, Bajot F, Neuhoff S, et al. A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. Clin Pharmacokinet. 2014;53(1):73–87.
   PubMed Web of Science ®Google Scholar
• Van De Steeg E, Stránecký V, Hartmannová H, et al. Complete OATP1B1 and OATP1B3 deficiency causes human rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J ClinInvest. 2012;122:519–528.
   PubMed Web of Science ®Google Scholar
• Fan L, Zhang W, Guo D, et al. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther. 2008;83(3):471–476.
   PubMed Web of Science ®Google Scholar
• Karlgren M, Vildhede A, Norinder U, et al. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012;55(10):4740–4763.
   PubMed Web of Science ®Google Scholar
• Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002;71(1):11–20.
   PubMed Web of Science ®Google Scholar
• Imanaga J, Kotegawa T, Imai H, et al., The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics. 21(2): 84–93. 2011.
   PubMed Web of Science ®Google Scholar
• Jeon H, Jang IJ, Lee S, et al. Apple juice greatly reduces systemic exposure to atenolol. Br J Clin Pharmacol. 2013;75(1):172–179.
   PubMed Web of Science ®Google Scholar
• Dong AN, Ahemad N, Pan Y, et al. Functional and structural characterisation of common cytochrome P450 2D6 allelic variants—roles of Pro34 and Thr107 in catalysis and inhibition. Naunyn Schmiedebergs Arch Pharmacol. 2019;392(8):1015–1029.
   PubMed Web of Science ®Google Scholar
• Verbeurgt P, Mamiya T, Oesterheld J. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics. 2014;15(5):655–665.
   PubMed Web of Science ®Google Scholar
• Bartsch H, Nair U, Risch A, et al. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev. 2000;9(1):3–28.
   PubMed Web of Science ®Google Scholar
• Paulík A, Grim J, Filip S. Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer. Acta Medica (Hradec Kral). 2012;55(4):153–159.
   Google Scholar
• Teft WA, Welch S, Lenehan J, et al., OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. Br J Cancer. 112(5): 857–865. 2015.
   PubMed Web of Science ®Google Scholar
• Takane H, Kawamoto K, Sasaki T, et al. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. Cancer Chemother Pharmacol. 2009;63(6):1165–1169.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Garcia-Bournissen F, Kim R, et al. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1. Arch Dis Child. 2009;94(12):981–982.
   PubMed Web of Science ®Google Scholar
• Sai K, Saito Y, Maekawa K, et al. Additive Effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol. 2010;66(1):95–105.
   PubMed Web of Science ®Google Scholar
• Smith NF, Figg WD, Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol Vitr. 2006;20(2):163–175.
   PubMed Web of Science ®Google Scholar
• Kim SR, Sai K, Tanaka-Kagawa T, et al. Haplotypes and a novel defective allele of CES2 found in a Japanese population. Drug Metab Dispos. 2007;35(10):1865–1872.
   PubMed Web of Science ®Google Scholar
• Rouits E, Charasson V, Pétain A, et al. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer. 2008;99(8):1239–1245.
   PubMed Web of Science ®Google Scholar
• Kerb R, Aynacioglu AS, Brockmöller J, et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. 2001;1(3):204–210.
   PubMedGoogle Scholar
• Shengule S, Kumbhare K, Patil D, et al. Herb-drug interaction of nisha amalaki and curcuminoids with metformin in normal and diabetic condition: A disease system approach. Biomed Pharmacother. 2018;101:591–598.
   PubMed Web of Science ®Google Scholar
• Thomas MC, Tikellis C, Kantharidis P, et al. The role of advanced glycation in reduced organic cation transport associated with experimental diabetes. J Pharmacol Exp Ther. 2004;311(2):456–466.
   PubMed Web of Science ®Google Scholar
• Zhai T, Wang J, Sun L, et al. The effect of streptozotocin and alloxan on the mrna expression of rat hepatic transporters in vivo. AAPS PharmSciTech. 2015;16(4):767–770.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang H, Xu J, et al. Prediction of atorvastatin pharmacokinetics in high-fat diet and low-dose streptozotocin-induced diabetic rats usin a semiphysiologically based pharmacokinetic model involving both enzymes and transporters. Drug Metab Dispos. 2019;47(10):1066–1079.
   PubMed Web of Science ®Google Scholar
• Köck K, Xie Y, Hawke RL, et al. Interaction of silymarin flavonolignans with organic anion-transporting polypeptides. Drug Metab Dispos. 2013;41(5):958–965.
   PubMed Web of Science ®Google Scholar
• Hawke RL, Schrieber SJ, Soule TA, et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol. 2010;50(4):434–449.
   PubMed Web of Science ®Google Scholar
• Dickinson A, MacKay D. Health habits and other characteristics of dietary supplement users: a review. Nutr J. 2014;13(1):14.
   PubMedGoogle Scholar
• Roe AL, Paine MF, Gurley BJ, et al. Assessing natural product-drug interactions: an end-to-end safety framework. Regul Toxicol Pharmacol. 2016;76:1–6.
   PubMed Web of Science ®Google Scholar
• Lake AD, Novak P, Fisher CD, et al. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2011;39(10):1954–1960.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wen Q, Li SF, et al. Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma. Oncotarget. 2016;7(31):50612–50623.
   PubMedGoogle Scholar
• Clarke JD, Hardwick RN, Lake AD, et al. Synergistic interaction between genetics and disease on pravastatin disposition. J Hepatol. 2014;61(1):139–147.
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Germain GS, Harwood FC, et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 2004;64(7):2333–2337.
   PubMed Web of Science ®Google Scholar
• Toth EL, Li H, Dzierlenga AL, et al. Gene-by-environment interaction of Bcrp−/−and methionine- and choline-deficient diet–induced nonalcoholic steatohepatitis alters SN-38 disposition. Drug Metab Dispos. 2018;46(11):1478–1486.
   PubMed Web of Science ®Google Scholar
• Silvestri L, Sonzogni L, De Silvestri A, et al. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. Int J Cancer. 2003;104(3):310–317.
   PubMed Web of Science ®Google Scholar
• Zeng T, Guo -F-F, Zhang C-L, et al. Roles of cytochrome P4502E1 gene polymorphisms and the risks of alcoholic liver disease: a meta-analysis. PLoS One. 2013;8(1):e54188.
   PubMed Web of Science ®Google Scholar
• Sookoian S, Castaño G, Gianotti TF, et al. Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease. J Nutr Biochem. 2009;20(10):765–770.
   PubMed Web of Science ®Google Scholar
• Izumi S, Nozaki Y, Kusuhara H, et al. Relative Activity Factor (RAF)-based scaling of uptake clearance mediated by Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 in human hepatocytes. Mol Pharm. 2018;15(6):2277–2288.
   PubMed Web of Science ®Google Scholar
• Nordell P, Winiwarter S, Hilgendorf C. Resolving the distribution-metabolism interplay of eight OATP substrates in the standard clearance assay with suspended human cryopreserved hepatocytes. Mol Pharm. 2013;10(12):4443–4451.
   PubMedGoogle Scholar
• Li CY, Gupta A, Gáborik Z, et al. Organic anion transporting polypeptide-mediated hepatic uptake of glucuronide metabolites of androgens. Mol Pharmacol. 2020;98(3):234–242.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ruggiero M, Hagenbuch B. OATP1B3 expression and function is modulated by coexpression with OCT1, OATP1B1, and NTCP. Drug Metab Dispos. 2020;48(8):622–630.
   PubMed Web of Science ®Google Scholar
• Crawford RR, Potukuchi PK, Schuetz EG, et al. Beyond competitive inhibition: regulation of ABC transporters by kinases and protein-protein interactions as potential mechanisms of drug-drug interactions. Drug Metab Dispos. 2018;46(5):567–580.
   PubMed Web of Science ®Google Scholar
• Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: current concepts and remaining challenges. Hepatol Res. 2015;45(1):20–28.
   PubMed Web of Science ®Google Scholar
• Jennison E, Patel J, Scorletti E, et al. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019;95(1124):314–322.
   PubMed Web of Science ®Google Scholar
• Türk D, Hanke N, Wolf S, et al. Physiologically based pharmacokinetic models for prediction of complex CYP2C8 and OATP1B1 (SLCO1B1) drug–drug–gene interactions: a modeling network of gemfibrozil, repaglinide, pioglitazone, rifampicin, clarithromycin and itraconazole. Clin Pharmacokinet. 2019;58(12):1595–1607.
   PubMed Web of Science ®Google Scholar
• Xu R, Ge W, Jiang Q. Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban. Eur J Clin Pharmacol. 2018;74(6):755–765.
   PubMed Web of Science ®Google Scholar